Sign In
NASDAQ:ADMA
ADMA Biologics Inc Stock Earnings Reports
$21.73
+0.340 (+1.59%)
At Close: Apr 23, 2025
ADMA Biologics Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| EPS estimate | $0.160 |
| EPS actual | - |
| Revenue estimate | 116.4M |
| Revenue actual | - |
| Expected change | +/- 5.34% |
Q4 2024
Missed
$0.140 (-6.67%)
| Release date | Mar 03, 2025 |
| EPS estimate | $0.150 |
| EPS actual | $0.140 |
| EPS Surprise | -6.67% |
| Revenue estimate | 108.65M |
| Revenue actual | 117.549M |
| Revenue Surprise | 8.19% |
Q3 2024
Beat
$0.150 (15.38%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.130 |
| EPS actual | $0.150 |
| EPS Surprise | 15.38% |
| Revenue estimate | 113.4M |
| Revenue actual | 119.839M |
| Revenue Surprise | 5.68% |
Q2 2024
Beat
$0.130 (62.50%)
| Release date | Aug 08, 2024 |
| EPS estimate | $0.0800 |
| EPS actual | $0.130 |
| EPS Surprise | 62.50% |
| Revenue estimate | 86.41M |
| Revenue actual | 107.191M |
| Revenue Surprise | 24.05% |
Last 4 Quarters for ADMA Biologics
Below you can see how ADMA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $12.19 |
| EPS estimate | $0.0800 |
| EPS actual | $0.130 |
| EPS surprise | 62.50% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $11.69 |
| Aug 05, 2024 | $11.30 |
| Aug 06, 2024 | $11.86 |
| Aug 07, 2024 | $11.45 |
| Aug 08, 2024 | $12.19 |
| Aug 09, 2024 | $15.96 |
| Aug 12, 2024 | $16.45 |
| Aug 13, 2024 | $17.27 |
| Aug 14, 2024 | $17.57 |
| 4 days before | 4.28% |
| 4 days after | 44.13% |
| On release day | 30.93% |
| Change in period | 50.30% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $19.72 |
| EPS estimate | $0.130 |
| EPS actual | $0.150 |
| EPS surprise | 15.38% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $19.37 |
| Nov 04, 2024 | $19.11 |
| Nov 05, 2024 | $18.83 |
| Nov 06, 2024 | $19.67 |
| Nov 07, 2024 | $19.72 |
| Nov 08, 2024 | $22.62 |
| Nov 11, 2024 | $22.48 |
| Nov 12, 2024 | $21.78 |
| Nov 13, 2024 | $21.47 |
| 4 days before | 1.81% |
| 4 days after | 8.87% |
| On release day | 14.71% |
| Change in period | 10.84% |
Q4 2024
Missed
| Release date | Mar 03, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $15.83 |
| EPS estimate | $0.150 |
| EPS actual | $0.140 |
| EPS surprise | -6.67% |
| Date | Price |
|---|---|
| Feb 25, 2025 | $15.44 |
| Feb 26, 2025 | $15.78 |
| Feb 27, 2025 | $15.44 |
| Feb 28, 2025 | $16.39 |
| Mar 03, 2025 | $15.83 |
| Mar 04, 2025 | $17.01 |
| Mar 05, 2025 | $17.68 |
| Mar 06, 2025 | $16.91 |
| Mar 07, 2025 | $17.02 |
| 4 days before | 2.53% |
| 4 days after | 7.52% |
| On release day | 7.45% |
| Change in period | 10.23% |
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | $0.160 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 16, 2025 | $21.23 |
| Apr 17, 2025 | $21.31 |
| Apr 21, 2025 | $19.64 |
| Apr 22, 2025 | $21.39 |
| Apr 23, 2025 | $21.73 |
ADMA Biologics Earnings Call Transcript Summary of Q4 2024
Financial Highlights
- Adjusted EBITDA: Grew significantly to $164.6 million, reflecting a 309% increase from the previous year.
- GAAP Net Income: Reported at $197.7 million for 2024, improving from a net loss of $28.2 million in 2023.
- Quarterly Growth: Q4 2024 revenue was $117.5 million, a 59% increase compared to Q4 2023.
Future Guidance
- Revenue Projections: Guidance for 2025 is set to exceed $490 million and to reach $605 million by 2026.
- Adjusted EBITDA Projections: Expected to surpass $225 million in 2025 and $305 million in 2026.
- Adjusted Net Income: Guidance raised to over $175 million in 2025 and $235 million in 2026.
Business and Operational Updates
- ASCENIV: The company anticipates continued demand growth for ASCENIV amidst high acceptance among healthcare providers and patients, with patient queue systems in place due to increasing demand.
- Plasma Supply: ADMA has secured significant third-party high-titer plasma supply contracts, enhancing collection capacity by approximately fivefold.
- Enhanced Yield Production Process: Anticipated mid-year 2025 regulatory approval for an enhanced yield process that could increase production output by 20%.
Strategic Focus
- R&D Pipeline: Development of SG-001 targeting strep pneumonia, with potential to contribute $300 million to $500 million in annual revenue if approved.
- Intellectual Property: Strong protection for ASCENIV and SG-001, securing long-term revenue potential and brand durability through at least 2037.
Financial Strength
- Cash Position: At year-end 2024, total cash holdings exceeded $103 million, giving ADMA a net cash position relative to outstanding debt of $75 million.
- Debt Management: The company is focused on capital allocation strategies that enhance shareholder value, considering options for debt refinancing.
Closing Remarks
ADMA Biologics is strategically positioned for continued growth through operational excellence, innovative therapies catered towards immune-compromised patients, and solid financial health that supports future initiatives. The leadership expresses confidence in achieving targeted revenue milestones and maintaining competitive advantages in their sector.
ADMA Biologics Earnings History
Earnings Calendar
FAQ
When is the earnings report for ADMA?
ADMA Biologics Inc (ADMA) has scheduled its earnings report for May 08, 2025 before the markets open.
What is the ADMA price-to-earnings (P/E) ratio?
ADMA P/E ratio as of Apr 23, 2025 (TTM) is 23.49.
What is the ADMA EPS forecast?
The forecasted EPS (Earnings Per Share) for ADMA Biologics Inc (ADMA) for the first fiscal quarter 2025 is $0.160.
What are ADMA Biologics Inc's retained earnings?
On its balance sheet, ADMA Biologics Inc reported retained earnings of $117.55 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
